Dr. Samarsky is one of the pioneers and an internationally recognized expert in the field of RNAi therapeutics. Dr. Samarsky will have two roles: (1) to lead Sirnaomics’ RNAi technology development and secure its leadership position; and (2) to facilitate technology collaborations and therapeutic partnerships.
Sirnaomics announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first oncology IND application. The IND approval will allow for the study of the Company’s lead product candidate, STP705, in patients with advanced cholangiocarcinoma (CCA).
Sirnaomics announced today that David Evans, Ph.D., a co-founder of the company, has been appointed as Chief Scientific Officer.
This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.
Dr. Long will be responsible for clinical studies performed in China. His extensive experience and knowledge in preclinical and clinical regulations will strengthen Sirnaomics clinical programs for novel siRNA therapeutic development in China.